Search
By July 31, twelve public funds in the market had achieved a remarkable net value growth rate of over 100% within the year, effectively 'doubling' their performance. These exceptional products primarily concentrate on innovative drugs, pharmaceuticals, biotechnology, and healthcare sectors. Their stellar performance is intimately tied to the robust momentum of the Hong Kong stock market's innovative drug sector. At the forefront, ChinaAMC Hong Kong Advantage Select A leads with a year-to-date net value growth rate of 143.24%. As a QDII fund dedicated to Hong Kong stock innovative drugs, it not only topped the performance rankings in the first half of the year but also had all ten of its top holdings at the end of the second quarter in Hong Kong stock innovative drug stocks.
-
C114 Communication Network -
Communication Home
